Clinical Efficacy of Olaparib in IDH1/IDH2- Mutant Mesenchymal Sarcomas.
Joseph Paul EderDeborah B DoroshowKhanh T DoVicki L KeedyJeffrey S SklarPeter M GlazerRanjit BindraGeoffrey I ShapiroPublished in: JCO precision oncology (2022)
These results indicate preliminary activity of PARP inhibition in patients with IDH1/2-mutant chondrosarcoma and pulmonary epithelioid hemangioendothelioma. Further studies of PARP inhibitors alone and in combination in this patient population are warranted.